HEPATOCELLULAR CARCINOMA (HCC)

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. The study involv…

This study is looking at how well a treatment called TheraSphere® works for people with early-stage liver cancer. The treatment uses tiny radioactive beads to target and destroy cancer cells from inside the liver. Researchers will track 200 patients in Korea to see how long they …

This study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in one day instead of two for people with small tumors (under 5 cm). Normally, patients need two separate hospital visits, but this streamlined approach skips an extra imaging step. …

This early-phase study was designed to test a new treatment combination for people with advanced liver cancer that can be surgically removed. Participants would have received three sessions of focused radiation to the tumor, along with immunotherapy drugs (one dose of tremelimuma…

This study tests a new, more stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in 30 people who cannot have surgery or choose not to. The treatment combines a procedure called TACE (which blocks the tumor's blood supply and delivers chemo) …

This phase 3 trial tests whether a combination of two drugs (camrelizumab and rivoceranib) can prevent liver cancer from returning in patients who have had surgery or ablation and are at high risk of recurrence. About 687 participants will either receive the drug combination or b…

This study tests a combination of two drugs (toripalimab and bevacizumab) along with three different artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the …

This early-phase study tests whether adding two drugs (JS014 and toripalimab) to a standard liver cancer procedure (TACE) is safe and helps control tumors in people with advanced liver cancer that cannot be removed by surgery. About 20 adults aged 18-75 with untreated, measurable…

This study tests whether a two-drug immunotherapy combination (durvalumab and bevacizumab) given after a precise internal radiation treatment (TARE) can help control liver cancer that cannot be removed by surgery. About 58 adults with this type of liver cancer will receive the ra…

This study tests a new drug combination (QL1706 plus local therapy or targeted drugs) in 62 adults with liver cancer that worsened after initial targeted-immunotherapy. The goal is to see if this second-line approach can shrink tumors and control the disease. Participants receive…

This study compares a shortened MRI scan to the standard ultrasound for finding liver cancer in 820 adults with liver cirrhosis. Researchers will also check if blood markers can help with diagnosis. The goal is to see if the faster MRI is more accurate and cost-effective for rout…

This study collects tumor tissue from about 416 people with various advanced cancers to develop and train a new diagnostic platform called Elephas. The goal is to see how accurately the platform can predict whether a patient will respond to immunotherapy, compared to standard met…

This study looks back at 500 liver cancer patients whose tumors became small enough for surgery after a mix of treatments (TACE, lenvatinib, and an immunotherapy). Researchers want to see if patterns in medical scans and patient data can predict who does better with surgery versu…